The products are designed to work with Horizon's Edit-R predesigned synthetic single guide RNA and CRISPR guide RNA to create streamlined CRISPR gene editing and modulation workflows. The cell lines are generated using Edit-R lentiviral particles with a blasticidin resistance cassette.

Both lines are available in the same background to enable loss- and gain-of-function studies without the need to engineer specific cell lines. The time and money saved by removing this step will help researchers increase productivity and simplify CRISPR workflows.

The complete package of quality control-validated cell lines with Edit-R predesigned single guide RNA products and DharmaFect transfection reagents will be bundled for sale.

ReNeuron to manufacture exosomes for gene therapies
ReNeuron signed a research evaluation agreement with a U.S. biotechnology company for the use of its proprietary exosomes for the delivery of novel gene...

Illumina Accelerator announces new genomics startups
Illumina has chosen seven companies to join the first global cohort of Illumina Accelerator, its startup incubator that partners with entrepreneurs to...

Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Regeneron Pharmaceuticals and Intellia Therapeutics have expanded their existing collaboration to provide Regeneron with rights to develop in vivo CRISPR/Cas9-based...

MilliporeSigma granted foundational CRISPR-Cas9 U.S. patents
MilliporeSigma announced on May 11 that two of its CRISPR-Cas9-assisted genome-editing patents have been allowed in the U.S. The allowances cover cleavage...

Caribou, MaxCyte enter CRISPR license agreement
Caribou Biosciences and MaxCyte have announced a clinical and commercial license agreement for the development of Carbiou's CAR-T cell therapy program.